SARIQ KASALLIK (GEPATIT A, B, C)
Keywords:
gepatit A, gepatit B, gepatit C, sariqlik, jigar kasalligi, virusli infeksiya, immunizatsiya, antiviral terapiya, diagnostika.Abstract
Ushbu maqolada gepatit A, B va C turlari bo‘yicha so‘nggi epidemiologik holatlar, klinik kechish, tashxis usullari va zamonaviy davolash strategiyalari tahlil qilinadi. Gepatit A asosan ifloslangan suv yoki oziq-ovqat orqali yuqadigan o‘tkir infeksion kasallik bo‘lib, o‘z vaqtida aniqlansa to‘liq sog‘ayish bilan yakunlanadi. Gepatit B va C esa qon orqali yoki jinsiy aloqa yo‘li bilan yuqadi va surunkali shakllarga o‘tib, jigar sirrozi yoki jigar saratoniga olib kelishi mumkin. Maqolada zamonaviy antiviral davo vositalari, vaksinalar, profilaktika choralarining samaradorligi va O‘zbekiston sharoitida mavjud muammolar yoritilgan. Shuningdek, global sog‘liqni saqlash strategiyalarining milliy darajadagi implementatsiyasi muhokama qilinadi.
References
1. World Health Organization (WHO). (2022). Global hepatitis report. Geneva.
2. Shepard, C.W., Simard, E.P., Finelli, L., Fiore, A.E., & Bell, B.P. (2006). "Hepatitis B virus infection: epidemiology and vaccination". Epidemiologic Reviews, 28(1), 112–125.
3. Lavanchy, D. (2009). "The global burden of hepatitis C". Liver International, 29(S1), 74–81.
4. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2024). Virusli gepatitlar bo‘yicha statistik axborot. www.minzdrav.uz
5. Lok, A.S.F., & McMahon, B.J. (2007). "Chronic hepatitis B". Hepatology, 45(2), 507–539.
6. Terrault, N.A., et al. (2018). "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance". Hepatology, 67(4), 1560–1599.
7. EASL. (2020). "Clinical Practice Guidelines: Management of hepatitis C virus infection". Journal of Hepatology, 73(6), 1170–1218.
8. Jacobson, I.M., et al. (2013). "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options". New England Journal of Medicine, 368(20), 1867–1877.